- Home
- PGEN vs XXI Comparison
PGEN vs XXI Comparison
Compare PGEN & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGEN | XXI |
|---|---|---|
| Founded | 1998 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2013 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PGEN | XXI |
|---|---|---|
| Price | $7.02 | $5.48 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.65 | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 1.4M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $2,335.22 | N/A |
| Revenue Next Year | $85.34 | N/A |
| P/E Ratio | $223.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $4.15 |
| 52 Week High | $8.98 | $11.49 |
Technical Indicators
Market Signals| Indicator | PGEN | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 39.45 |
| Support Level | $6.57 | $5.02 |
| Resistance Level | $7.44 | $5.71 |
| Average True Range (ATR) | 0.42 | 0.34 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 55.14 | 14.92 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.